This Report Provides In-Depth Analysis of the Cardiac Safety Services Market Report Prepared by P&S Intelligence, Segmented by Type (Integrated services, Standalone services), Type of Service (ECG/Hotler measurement service, Blood pressure measurement services, Cardiovascular imaging, Thorough QT studies), End User (Pharmaceutical and biopharmaceutical companies, Contract research organizations, Academic and research institutes), and Geographical Outlook for the Period of 2019 to 2032
Explore the market potential with our data-driven report
Cardiac Safety Services Market Overview
The cardiac safety services market size was USD 811 million in 2024, and it will grow by 14.1% during 2025–2032, reaching USD 2305.1 million by 2032.
This is because these services assist in supporting and designing clinical trials and other research studies required to monitor cardiac health and are focused on monitoring a complete cardiac protection profile across different phases of clinical experimentation.
Moreover, the increasing number of drug launches and clinical trials, the growing healthcare expenditure, the surging investments by pharmaceutical companies, the advent of advanced and high-tech healthcare products, and strategic initiatives by leading players across the world are driving the market growth. Further, the rising aging population and sedimentary lifestyle among millennials are boosting the demand for healthcare solutions, such as cardiac safety.
Heart healthcare solutions have been in high demand since the COVID-19 pandemic, as the disease exerted a high load on the existing healthcare industry. The virus most commonly affected the respiratory system and it is also observed that it led to all types of serious heart ailments. The lung damage triggered by the virus prevents oxygen-rich blood to reach the heart muscle, which, in turn, damages its tissue. It disrupts the electrical signals, which help the heart to beat properly, which reduces the pumping ability or may lead to irregular rhythms, also known as arrhythmia, or make an existing arrhythmia worse.
For instance, as per an article published in October 2022 in BMJ Journals, a study was conducted, which exhibited that people admitted with COVID-19 had a high risk of occurrence of cardiovascular diseases (CVDs), including heart failure, stroke, myocardial infarction, venous thromboembolism, and atrial fibrillation, among others. Therefore, the pandemic had a substantial positive impact on the market.
Cardiac Safety Services Market Trends & Drivers
Integration of Artificial Intelligence (AI) and Machine Learning (ML) Is Key Trend
There is a growing need for faster and more-accurate cardiac data analysis in clinical trials, which AI and ML can provide.
AI reduces the time and cost associated with manual ECG and cardiac event evaluations.
The volume of data from wearable and remote monitoring devices is increasing, and AI is essential to process this data efficiently.
The Cardiac Safety Research Consortium (CSRC) is a partnership between the FDA, industry leaders, and academic institutions, working to improve cardiac safety in clinical trials.
It guides regulators and researchers in addressing heart-related issues in both new and existing products.
Drug development is becoming more complex and regulatory agencies now expect more-thorough cardiac safety assessments.
AI provides advanced tools for predicting the side-effects of new compounds on the heart and improving the quality and consistency of those assessments.
The shift toward decentralized and virtual clinical trials requires remote monitoring, which relies heavily on AI for real-time cardiac analysis.
AI enables the early detection of life-threatening cardiac issues, improving patient safety and trial outcomes.
The Healthy China 2030 initiative aims to expand access to advanced healthcare technologies and clinical trials with a focus on cardiac health.
Pharmaceutical companies and CROs are under pressure to deliver faster results with fewer resources, making AI a cost-effective solution.
Integration with AI supports personalized medicine by analyzing individual patient data for tailored cardiac safety profiles.
The technology is becoming more accessible and accepted in healthcare as AI-driven solutions are now easier to implement and scale.
Rising Prevalence of Cardiovascular Diseases (CVDs) Is Major Growth Driver
The increasing prevalence of chronic diseases is one of the key driving forces for the expansion of the cardiac safety services market.
CVDs are the leading cause of death and account for around 20 million deaths each year globally.
CVD includes various types of disorders such as heart coronary disease, rheumatic disease, cerebrovascular disease, and other conditions.
IQVIA’s self-collection safety lab panel streamlines the data collection process, making it more efficient, effective, reliable and convenient for U.S. clinical trial participants.
The reason for such diseases and stroke includes unhealthy behavioral practices such as physical inactivity, unhealthy diet, tobacco use, and high alcohol consumption.
The negative effects of such behavioral practices may cause elevated blood pressure, high blood lipids, raised blood glucose, overweight, and obesity.
Apart from an inactive lifestyle and intake of unhealthy diets, the deposition of fats in arteries over many years leads to life-threatening diseases.
The reason is the stiffness in large arteries that exerts pressure on the heart to efficiently supply blood but it pumps less efficiently.
Hence, the growing complications of CVDs with old age are projected to increase the adoption of ECG/Holter measurement services in the forecast period.
Also, with a rise in the aged population, the demand for CVD care is expected to increase.
The integrated category held the larger market share, of 80%, in 2024. This is because it is provided as a package of services to biopharmaceutical and pharmaceutical companies. These core lab services offer a set of heart health facilities that are required from start to the finish of a procedure, such as imaging solutions, TQT studies, and profile QT studies. These services are also used in monitoring several physiological parameters to aid in the real-time assessment of the heart rate of patients. As a result, they help enhance and advance clinical trials for pharmaceutical and biopharmaceutical development cycles.
The types analyzed here are:
Integrated Services (Larger Category)
Standalone Services (Faster-Growing Category)
Service Analysis
The ECG/Holter measurement category held the largest market share, of 65%, in 2024. This is because continuous and painless monitoring of the heart with AI/ML helps detect arrhythmias, changes in the QT interval, ischemia, and several other cardiac events. The FDA and EMA require that ECGs are used during early- and late-phase clinical trials, mainly for drugs that can affect the heart’s function.
The blood pressure measurement category will grow at the highest CAGR during the forecast period. This is because hypertension is a common danger for patients as it is linked to heart failure, stroke, and many other major health problems. For drug trials in the cardiovascular, nephrology, and metabolic disease areas, regular measurement of the blood pressure is important. Efforts to increase access to ambulatory blood pressure monitoring and remote digital solutions for real-time monitoring are gaining ground.
The pharmaceutical and biopharmaceutical companies category held the largest market share, of 75%, in 2024. This is because they run many clinical trials around the world for new medicines, which they need to ensure are safe for the heart. Heart safety checks are important at every stage of drug testing, especially for pharmaceuticals that could affect how it works. As rules and guidelines become stricter, the demand for these heart safety services is growing.
The contract research organizations category will grow at the highest CAGR during the forecast period. This is because CROs can help medical organizations run clinical trials and also provide support services, including evaluations of heart safety. Outsourcing these activities to CROs is popular with companies as it allows them to concentrate on their key tasks and still ensure their drugs are safe. Advanced heart safety tools are being used by CROs to reduce time and enhance accuracy during trials.
The end uses analyzed here are:
Pharmaceutical and Biopharmaceutical Companies (Largest Category)
Contract Research Organizations (Fastest-Growing Category)
Academic and Research Institutes
Drive strategic growth with comprehensive market analysis
North America held the largest market share, of 40%, in 2024, because the rise in the elderly population, increase in the number of clinical trials, and the introduction of innovative cardiac safety products by giant players. Further, the market is driven by the availability of technologically advanced products, a rise in disposable income, and high healthcare expenditure in the region.
As per the latest available data from 2024, approximately 605,000 new heart attacks and 200,000 recurrent heart attacks occur annually in the U.S. Additionally, 170,000 of those are silent, meaning they occur without significant symptoms.
Europe will grow at the highest CAGR during the forecast period. This is mainly attributed to the developed healthcare infrastructure and high healthcare investment. For instance, western European countries, such as Germany, France, the U.K., and Switzerland, have a developed healthcare sector, owing to which new technology and diagnostic procedures are more frequently used in this part of the region. Further, the rapidly increasing percentage of an aging population and the increasing life expectancy in central and eastern European countries are driving the demand for healthcare solutions.
Furthermore, in Europe, CVD causes more than three million deaths every year and accounts for around 37% of all deaths. It has been observed that death rates from both stroke and ischemic heart disease (IHD) are generally higher in eastern and central Europe than in other parts of the region. Therefore, the rise in CVD cases is further expected to bolster the need for heart care services in the future.
The regions and countries analyzed in this report are:
North America (Largest Regional Market)
U.S. (Largest Category)
Canada (Fastest-Growing Category)
Europe (Fastest-Growing Regional Market)
Germany (Largest Category)
U.K. (Fastest-Growing Category)
France
Italy
Russia
Rest of Europe
Asia-Pacific
China (Largest Category)
India (Fastest-Growing Category)
Japan
South Korea
Australia
Rest of APAC
Latin America
Brazil (Largest Category)
Mexico (Fastest-Growing Category)
Rest of LATAM
Middle East and Africa
Saudi Arabia (Largest Category)
South Africa (Fastest-Growing Category)
U.A.E.
Rest of MEA
Cardiac Safety Services Market Share
The market is fragmented in nature because of a large number of independent service providers. This includes both big companies that have been around for a while and newer businesses, each working to provide different services and online tools. No one company is dominant as players try to stand out by coming up with new ideas and technology. Companies are teaming up with each other, buying other businesses, and using newer technology, especially artificial intelligence and real-time tracking, to enhance the process. This fragmentation helps new products come about and gives both big and small companies a chance to do well.
Key Cardiac Safety Services Companies :
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace Inc.
Ncardia
Certara
Eurofins Scientific SE
SGS SA
Banook Group
Celerion
Richmond Pharmacology
Shanghai Medicilon Inc.
Cardiac Safety Services Market News
In March 2025, Koninklijke Philips N.V. deployed several AI-driven enhancements in its Compact Ultrasound 5500CV for cardiac imaging. Designed for use on children, newborns, less-mobile patients, and the elderly at their bedside at community-based medical centers and hospitals, the new system cuts procedure time by up to half.
In January 2025, Koninklijke Philips N.V. entered into a collaboration with Myocardial Solutions Inc. to develop AI-powered cardiac MRI systems to detect cardiotoxicity from cancer drugs and prevent the resulting heart diseases.
In May 2024, VivaLNK Inc. introduced a new technology for Holter monitoring and mobile cardiac telemetry (MCT), which combines remote patient monitoring with advanced algorithms to detect heart rhythm problems.
In November 2023, Clario launched an AI-powered tool to check the quality of ECG data in clinical trials, to spot and fix issues early. This tool works with the firm’s EPQT solution to make heart safety testing faster and more efficient.
Want a report tailored exactly to your business need?
Leading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Client Testimonials
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Unmatched Standards
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
Complete Data Security
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws